vs
丹纳赫（DHR）与恩智浦（NXPI）财务数据对比。点击上方公司名可切换其他公司
丹纳赫的季度营收约是恩智浦的1.9倍（$6.0B vs $3.2B），恩智浦净利率更高（35.3% vs 17.3%，领先18.0%），丹纳赫同比增速更快（3.7% vs -5.0%），丹纳赫自由现金流更多（$1.1B vs $714.0M），过去两年丹纳赫的营收复合增速更高（1.8% vs 0.9%）
丹纳赫是总部位于美国华盛顿特区的医疗健康企业，聚焦生物技术、生命科学与诊断领域的产品研发。公司下设三大业务板块：生物技术板块开发治疗相关产品，生命科学板块覆盖疾病溯源、新疗法研发、药物疫苗与基因编辑技术的测试生产，诊断板块研发检测仪器，为全球生命健康产业提供核心支持。
恩智浦是总部位于荷兰埃因霍温的半导体设计与制造企业，为2024年市值排名欧洲第三的半导体公司。目前集团在全球30多个国家拥有约3.4万名员工，2024年总营收达126.1亿美元。
DHR vs NXPI — 直观对比
营收规模更大
DHR
是对方的1.9倍
$3.2B
营收增速更快
DHR
高出8.7%
-5.0%
净利率更高
NXPI
高出18.0%
17.3%
自由现金流更多
DHR
多$371.0M
$714.0M
两年增速更快
DHR
近两年复合增速
0.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $6.0B | $3.2B |
| 净利润 | $1.0B | $1.1B |
| 毛利率 | 60.3% | 59.5% |
| 营业利润率 | 22.6% | — |
| 净利率 | 17.3% | 35.3% |
| 营收同比 | 3.7% | -5.0% |
| 净利润同比 | 7.9% | 147.0% |
| 每股收益（稀释后） | $1.45 | $4.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DHRNXPI
| Q1 26 | $6.0B | $3.2B | ||
| Q4 25 | $6.8B | $3.3B | ||
| Q3 25 | $6.1B | $3.2B | ||
| Q2 25 | $5.9B | $2.9B | ||
| Q1 25 | $5.7B | $2.8B | ||
| Q4 24 | $6.5B | $3.1B | ||
| Q3 24 | $5.8B | $3.3B | ||
| Q2 24 | $5.7B | $3.1B |
净利润DHRNXPI
| Q1 26 | $1.0B | $1.1B | ||
| Q4 25 | $1.2B | $455.0M | ||
| Q3 25 | $908.0M | $631.0M | ||
| Q2 25 | $555.0M | $445.0M | ||
| Q1 25 | $954.0M | $490.0M | ||
| Q4 24 | $1.1B | $495.0M | ||
| Q3 24 | $818.0M | $718.0M | ||
| Q2 24 | $907.0M | $658.0M |
毛利率DHRNXPI
| Q1 26 | 60.3% | 59.5% | ||
| Q4 25 | 58.0% | 54.2% | ||
| Q3 25 | 58.2% | 56.3% | ||
| Q2 25 | 59.3% | 53.4% | ||
| Q1 25 | 61.2% | 55.0% | ||
| Q4 24 | 59.5% | 53.9% | ||
| Q3 24 | 58.7% | 57.4% | ||
| Q2 24 | 59.7% | 57.3% |
营业利润率DHRNXPI
| Q1 26 | 22.6% | — | ||
| Q4 25 | 22.0% | 22.3% | ||
| Q3 25 | 19.1% | 28.1% | ||
| Q2 25 | 12.8% | 23.5% | ||
| Q1 25 | 22.2% | 25.5% | ||
| Q4 24 | 21.8% | 21.7% | ||
| Q3 24 | 16.5% | 30.5% | ||
| Q2 24 | 20.3% | 28.7% |
净利率DHRNXPI
| Q1 26 | 17.3% | 35.3% | ||
| Q4 25 | 17.5% | 13.6% | ||
| Q3 25 | 15.0% | 19.9% | ||
| Q2 25 | 9.3% | 15.2% | ||
| Q1 25 | 16.6% | 17.3% | ||
| Q4 24 | 16.6% | 15.9% | ||
| Q3 24 | 14.1% | 22.1% | ||
| Q2 24 | 15.8% | 21.0% |
每股收益（稀释后）DHRNXPI
| Q1 26 | $1.45 | $4.43 | ||
| Q4 25 | $1.69 | $1.80 | ||
| Q3 25 | $1.27 | $2.48 | ||
| Q2 25 | $0.77 | $1.75 | ||
| Q1 25 | $1.32 | $1.92 | ||
| Q4 24 | $1.50 | $1.93 | ||
| Q3 24 | $1.12 | $2.79 | ||
| Q2 24 | $1.22 | $2.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.7B |
| 总债务越低越好 | — | $11.7B |
| 股东权益账面价值 | — | $10.9B |
| 总资产 | — | $27.1B |
| 负债/权益比越低杠杆越低 | — | 1.07× |
8季度趋势，按日历期对齐
现金及短期投资DHRNXPI
| Q1 26 | — | $3.7B | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.5B | ||
| Q2 25 | — | $3.2B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.9B |
总债务DHRNXPI
| Q1 26 | — | $11.7B | ||
| Q4 25 | $18.4B | $11.0B | ||
| Q3 25 | $16.9B | $11.0B | ||
| Q2 25 | $17.4B | $9.5B | ||
| Q1 25 | $16.5B | $10.2B | ||
| Q4 24 | $16.0B | $10.4B | ||
| Q3 24 | $17.5B | $9.7B | ||
| Q2 24 | $17.0B | $9.7B |
股东权益DHRNXPI
| Q1 26 | — | $10.9B | ||
| Q4 25 | $52.5B | $10.1B | ||
| Q3 25 | $51.1B | $10.0B | ||
| Q2 25 | $52.3B | $9.6B | ||
| Q1 25 | $50.8B | $9.3B | ||
| Q4 24 | $49.5B | $9.2B | ||
| Q3 24 | $51.3B | $9.4B | ||
| Q2 24 | $49.9B | $9.0B |
总资产DHRNXPI
| Q1 26 | — | $27.1B | ||
| Q4 25 | $83.5B | $26.6B | ||
| Q3 25 | $79.9B | $26.4B | ||
| Q2 25 | $81.6B | $25.3B | ||
| Q1 25 | $79.1B | $25.2B | ||
| Q4 24 | $77.5B | $24.4B | ||
| Q3 24 | $80.6B | $23.7B | ||
| Q2 24 | $78.6B | $23.2B |
负债/权益比DHRNXPI
| Q1 26 | — | 1.07× | ||
| Q4 25 | 0.35× | 1.09× | ||
| Q3 25 | 0.33× | 1.09× | ||
| Q2 25 | 0.33× | 0.99× | ||
| Q1 25 | 0.32× | 1.10× | ||
| Q4 24 | 0.32× | 1.13× | ||
| Q3 24 | 0.34× | 1.03× | ||
| Q2 24 | 0.34× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | — |
| 自由现金流经营现金流 - 资本支出 | $1.1B | $714.0M |
| 自由现金流率自由现金流/营收 | 18.2% | 22.4% |
| 资本支出强度资本支出/营收 | 4.0% | 2.5% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $5.3B | $2.7B |
8季度趋势，按日历期对齐
经营现金流DHRNXPI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $2.1B | $891.0M | ||
| Q3 25 | $1.7B | $585.0M | ||
| Q2 25 | $1.3B | $779.0M | ||
| Q1 25 | $1.3B | $565.0M | ||
| Q4 24 | $2.0B | $391.0M | ||
| Q3 24 | $1.5B | $779.0M | ||
| Q2 24 | $1.4B | $761.0M |
自由现金流DHRNXPI
| Q1 26 | $1.1B | $714.0M | ||
| Q4 25 | $1.7B | $793.0M | ||
| Q3 25 | $1.4B | $508.0M | ||
| Q2 25 | $1.1B | $696.0M | ||
| Q1 25 | $1.1B | $426.0M | ||
| Q4 24 | $1.5B | $261.0M | ||
| Q3 24 | $1.2B | $593.0M | ||
| Q2 24 | $1.1B | $576.0M |
自由现金流率DHRNXPI
| Q1 26 | 18.2% | 22.4% | ||
| Q4 25 | 25.5% | 23.8% | ||
| Q3 25 | 22.6% | 16.0% | ||
| Q2 25 | 18.4% | 23.8% | ||
| Q1 25 | 18.4% | 15.0% | ||
| Q4 24 | 23.0% | 8.4% | ||
| Q3 24 | 21.0% | 18.2% | ||
| Q2 24 | 19.7% | 18.4% |
资本支出强度DHRNXPI
| Q1 26 | 4.0% | 2.5% | ||
| Q4 25 | 5.4% | 2.9% | ||
| Q3 25 | 4.8% | 2.4% | ||
| Q2 25 | 4.2% | 2.8% | ||
| Q1 25 | 4.3% | 4.9% | ||
| Q4 24 | 7.9% | 4.2% | ||
| Q3 24 | 5.1% | 5.7% | ||
| Q2 24 | 5.0% | 5.9% |
现金转化率DHRNXPI
| Q1 26 | 1.28× | — | ||
| Q4 25 | 1.77× | 1.96× | ||
| Q3 25 | 1.83× | 0.93× | ||
| Q2 25 | 2.41× | 1.75× | ||
| Q1 25 | 1.36× | 1.15× | ||
| Q4 24 | 1.86× | 0.79× | ||
| Q3 24 | 1.85× | 1.08× | ||
| Q2 24 | 1.56× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
